{"id":26420,"date":"2021-03-03T13:28:14","date_gmt":"2021-03-03T12:28:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/?p=26420"},"modified":"2021-03-03T13:30:40","modified_gmt":"2021-03-03T12:30:40","slug":"dr-falk-pharma","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dr-falk-pharma\/","title":{"rendered":"Dr. Falk Pharma ranks 4th in the Pharma Trend Ranking 2020"},"content":{"rendered":"

\"DrDr. Falk Pharma is ranked 4th in the multidisciplinary ranking “Best Pharmaceutical Companies Germany” 2020<\/a> in the category “Large individual, medium-sized and international companies”. In Pharma Trend, Dr. Falk Pharma was recognised for innovation for the last time in 2018 with Jorveza\u00ae, which was awarded “The Most Innovative Product” by gastroenterologists in the OD category.
\n<\/p>\n

Specialist for digestion<\/h2>\n

Dr. Falk Pharma GmbH, founded in 1960 by the pharmacist Dr. Herbert Falk in Freiburg im Breisgau, has specialised in diseases of the liver and the digestive tract from the very beginning. The medicines, all ending in the syllable -falk, are established substances for inflammatory bowel diseases, constipation, diarrhoea and liver diseases. Germany is still the most important market for the family-owned company with its 200 employees; one third of all medicines are sold here. The company is currently experiencing stronger growth through worldwide sales subsidiaries. With a turnover of around \u20ac420 million and a net return around 25 per cent (2018), Falk is one of the most profitable pharmaceutical companies in Germany.<\/p>\n

Dr. Falk’s development department researches innovations on two tracks: through new substances as well as through new galenic preparations. For example, the well-known budesonide was developed in the form of an effervescent tablet and approved as the first therapy for eosinophilic oesophagitis; gastroenterologists voted Jorveza\u00ae the most innovative product in 2018.<\/p>\n

The guiding principle coined by the founder to provide doctors, pharmacists and patients with up-to-date and neutral information on diseases and therapies in gastroenterology and hepatology contributed significantly to the company’s success. A central role is played here by the associated Falk Foundation, which organises international symposia, supra-regional seminars and gastro forums and regional continuing education events. It offers an extensive medical literature service as well as patient information material. There is no need for a large sales force.<\/p>\n

Jorveza\u00ae: The most innovative product for gastroenterologists<\/h2>\n

In Pharma Trend, Dr Falk Pharma was awarded “The Most Innovative Product” for the first time in 2018 with Jorveza\u00ae by gastroenterologists for the treatment of eosinophilic oesophagitis. Decisive for the gastroenterologists’ award was the improved handling or form of application (58%), the novelty on the market (53%), the new, innovative mode of action (53%) and the expanded spectrum of action or improved effect (26%) as well as the simplified dosing of Jorveza\u00ae.<\/p>\n

First award for Dr. Falk Pharma for innovation and sustainability<\/h2>\n

Since the inception of the Pharma Trend benchmark study in 2000, 2017 was the first time the study was conducted among gastroenterologists. In 2018, Dr. Falk Pharma positioned itself among the top 3 finalists in the award “The Golden Tablet”, the award of companies for innovation and sustainability, and received the award “The Most Innovative Product” from gastroenterologists for Jorveza\u00ae.<\/p>\n

Awards for innovation and sustainability since 2000:<\/p>\n